anmelden
EQS-Adhoc: Termination of the botulinum toxin project
Werte in diesem Artikel
|
EQS-Ad-hoc: HAEMATO AG / Key word(s): Strategic Company Decision Werbung
Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out. After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to discontinue the project for a proprietary botulinum toxin. This decision has no impact on the company's operating business.
About HAEMATO: HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de. Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.ag End of Inside Information
15-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | HAEMATO AG |
| Lilienthalstraße 5c | |
| 12529 Schönefeld | |
| Germany | |
| Phone: | +49 (0)30 897 30 86 70 |
| Fax: | +49 (0)30 897 30 86 79 |
| E-mail: | ir@haemato.ag |
| Internet: | www.haemato.ag |
| ISIN: | DE000A289VV1 |
| WKN: | A289VV |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1774581 |
| End of Announcement | EQS News Service |
|
|
1774581 15-Nov-2023 CET/CEST
Ausgewählte Hebelprodukte auf HAEMATO
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf HAEMATO
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle HAEMATO Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
HAEMATO Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für HAEMATO nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.
